|
rs121913529
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
44% of the tumors were positive for G12D, 20% for G12V, and 10% for G12C.
|
27591291 |
2016 |
|
rs121913529
|
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
GeneticVariation
|
BEFREE |
NSCLC cell lines with mutant KRas-Gly12Asp had activated phosphatidylinositol 3-kinase (PI-3-K) and mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) signaling, whereas those with mutant KRas-Gly12Cys or mutant KRas-Gly12Val had activated Ral signaling and decreased growth factor-dependent Akt activation.
|
22247021 |
2012 |
|
rs121913529
|
|
Pancreatic Ductal Adenocarcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Pancreatic ductal adenocarcinoma (PDAC) commonly contains a mutation in K-Ras(G12D) and is characterized by a desmoplastic reaction composed of deregulated, proliferating cells embedded in an abnormal extracellular matrix (ECM).
|
23555182 |
2013 |
|
rs121913529
|
|
Lung Neoplasms
|
|
0.080 |
GeneticVariation
|
BEFREE |
Lung tumors were induced by doxycycline, and the therapeutic effects of Kras DNA vaccine were evaluated with delivery of Kras(G12D) plasmids.
|
25077772 |
2014 |
|
rs121913529
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Tumorigenesis was measured in the Kras(G12D/+);Ptf1a(Cre/+) mouse model of PDA; these mice were crossed with mice with pancreas-specific disruption of genes encoding PI3K p110α (Pik3ca), p110β (Pik3cb), or RAC1 (Rac1).
|
25311989 |
2014 |
|
rs121913529
|
|
Hemangiosarcoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Angiosarcoma showed a KRAS G12D point mutation, which is considered to be characteristic of vinyl chloride-induced angiosarcoma.
|
27544804 |
2016 |
|
rs121913529
|
|
Adult Angiosarcoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Angiosarcoma showed a KRAS G12D point mutation, which is considered to be characteristic of vinyl chloride-induced angiosarcoma.
|
27544804 |
2016 |
|
rs121913529
|
|
Childhood Angiosarcoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Angiosarcoma showed a KRAS G12D point mutation, which is considered to be characteristic of vinyl chloride-induced angiosarcoma.
|
27544804 |
2016 |
|
rs121913529
|
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
|
0.100 |
GeneticVariation
|
BEFREE |
G12D K-Ras increased cleavage of p35 to p25, a stable and greater activator of CDK5, thus implicating a role for CDK5 in early progression of PDAC.
|
21825040 |
2011 |
|
rs121913529
|
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.030 |
GeneticVariation
|
BEFREE |
G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.
|
26662311 |
2016 |
|
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer.
|
31309326 |
2019 |
|
rs121913529
|
|
Malignant neoplasm of colon and/or rectum
|
|
0.060 |
GeneticVariation
|
BEFREE |
G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer.
|
31309326 |
2019 |
|
rs121913529
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
G12D and Q61H are among the most prevalent cancer-causing mutations at the P-loop and switch 2 regions of KRAS, respectively.
|
31554397 |
2019 |
|
rs121913529
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
G12D and Q61H are among the most prevalent cancer-causing mutations at the P-loop and switch 2 regions of KRAS, respectively.
|
31554397 |
2019 |
|
rs121913529
|
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
GeneticVariation
|
BEFREE |
A biopsy acquired after disease progression revealed the original SDC4-ROS1 fusion along with a KRAS point mutation (p.G12D).We reviewed the related literature to determine the frequency of gene mutations in non-small cell lung cancer patients.
|
28971587 |
2018 |
|
rs121913529
|
|
Non-Small Cell Lung Carcinoma
|
|
0.790 |
GeneticVariation
|
BEFREE |
A doxycycline-inducible mouse model of KRAS (G12D) driven NSCLC and patient data was analyzed from multiple publicly accessible databases including TCGA, CCLE, NCBI GEO and Project Achilles.
|
26173780 |
2015 |
|
rs121913529
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
A KRAS G12A mutation was found in tumor removed from the finger.
|
22317887 |
2012 |
|
rs121913529
|
|
Carcinoma, Papillary
|
|
0.010 |
GeneticVariation
|
BEFREE |
A KRAS G12V mutation was detected in the plasma of 1 patient with stage IVA papillary carcinoma whose tissue contained the same mutation.
|
29498908 |
2018 |
|
rs121913529
|
|
Carcinosarcoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
A total of 3 different somatic mutations were identified: one KRAS (codon G12D) in a carcinosarcoma and two exon 20 PI3KCA mutations (H1047R and H1047Y) both in carcinosarcomas.
|
20122944 |
2010 |
|
rs121913529
|
|
Tumor Cell Invasion
|
|
0.020 |
GeneticVariation
|
BEFREE |
Activation of ERK2, but not ERK1, also occurs only in K-Ras(G12D)-mutated PDECs cultured in three-dimensions and is a necessary intracellular signaling event for invasion based upon pharmacologic and short hairpin RNA (shRNA) inhibition.
|
22160930 |
2012 |
|
rs121913529
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Adenoviral vectors containing the specific ribozymes with downstream suicide gene were constructed and then infection with the adenoviruses specifically downregulated KRAS G12V expression and killed KRAS G12V-harboring cancer cells additively upon pro-drug treatment, but it did not affect the growth of wild-type KRAS-expressing cells.
|
28153088 |
2017 |
|
rs121913529
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Adenoviral vectors containing the specific ribozymes with downstream suicide gene were constructed and then infection with the adenoviruses specifically downregulated KRAS G12V expression and killed KRAS G12V-harboring cancer cells additively upon pro-drug treatment, but it did not affect the growth of wild-type KRAS-expressing cells.
|
28153088 |
2017 |
|
rs121913529
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Administration of a CXCL16-neutralizing antibody to KRAS(G12D) mice reduced activation of PI3K signaling to AKT and NF-κB, blocking carcinogenesis.
|
25683115 |
2015 |
|
rs121913529
|
|
Adenocarcinoma
|
|
0.070 |
GeneticVariation
|
BEFREE |
After microdissecting and testing the adenocarcinoma and neuroendocrine components separately, it was found that the adenocarcinoma was positive for KRAS G12C mutation and the neuroendocrine component was positive for KRAS G12D mutation.
|
27597976 |
2016 |
|
rs121913529
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
After subsequent sequence optimization, we successfully generated KRpep-2d (Ac-RRRRCPLYISYDPVCRRRR-NH<sub>2</sub>) that inhibited enzyme activity of K-Ras(G12D) with IC<sub>50</sub> = 1.6 nM and significantly suppressed ERK-phosphorylation, downstream of K-Ras(G12D), along with A427 cancer cell proliferation at 30 μM peptide concentration.
|
28153726 |
2017 |